@entity2636 foam containing rhEGF as a dressing material for healing XXXX : Synthesis, characterization, in vitro and in vivo studies.

@entity1 @entity137 @entity6 @entity35 @entity2636
UNASSIGNED: @entity6 are a major health issue associated with @entity6 . To surmount this issue, we developed @entity2636 foams (PUFs) incorporating varying amounts of recombinant @entity1 epidermal growth factor (rhEGF) (rhEGF-PUFs) as a wound dressing for @entity6 . From electron microscopy images, it was found that the pore size of the rhEGF-PUFs surface (the wound contact layer) was less than 100 m, regardless of rhEGF content. The release of rhEGF from the PUFs was evaluated using an enzyme-linked immunosorbent assay. The result showed that the release of rhEGF was time and concentration dependent, i.e., the amount of released rhEGF significantly increased as the immersion time and the rhEGF content of the PUFs increased. In vitro @entity137 testing showed that rhEGF-PUFs increased the viability of HaCaT @entity1 keratinocytes and CCD986-sk @entity1 fibroblasts, which indicated that the incorporated rhEGF maintained its biological activity. In an in vitro scratch wound healing assay, the wound closure rate was faster in CCD986-sk @entity1 fibroblasts than in HaCaT @entity1 keratinocytes. Finally, the rhEGF-PUFs were evaluated as an in vivo treatment in a full-thickness wound model in diabetized @entity35 . The result indicated that compared with PUFs, rhEGF-PUFs accelerated wound healing by promoting wound contraction, re-epithelialization, collagen deposition and the formation of a skin appendage. These findings demonstrate that rhEGF-PUFs are a promising dressing for @entity6 .
